Search
Alizapride
go.drugbank.com/drugs/DB01425InvestigationalAlizapride is a dopamine antagonist that is capable of demonstrating both prokinetic and antiemetic effects. … This kind of pharmacological activity makes it effective for use in the treatment of various kinds of nausea and vomiting, including that which may occur postoperatively.
Setiptiline
go.drugbank.com/drugs/DB09304ExperimentalIn Japan, the company Mochida started its commercialization for the treatment of depression started in 1989. … Setiptiline is a tetracyclic antidepressant (TeCA) which acts as a noradrenergic and specific serotonergic antidepressant (NaSSA).
Subasumstat
go.drugbank.com/drugs/DB16406InvestigationalSubasumstat is under investigation in clinical trial NCT03648372 (A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics (PK) of TAK-981 in Adult Participants With Advanced … or Metastatic Solid Tumors or Relapsed/refractory Hematologic Malignancies and in a Subset With Coronavirus Disease 2019 (COVID-19)).
Azetukalner
go.drugbank.com/drugs/DB21551InvestigationalAzetukalner is under investigation in clinical trial NCT05718817 (An Open-label Study of XEN1101 in Epilepsy). Azetukalner has a monoisotopic molecular weight of 368.23 Da. … Azetukalner is a small molecule drug. The usage of the INN stem '-kalner' in the name indicates that Azetukalner is a opener of calcium-activated (maxi-K) K+-channel.
HZT-501
go.drugbank.com/drugs/DB05369InvestigationalHZT-501 is a combination product including ibuprofen and the acid reducing agent famotidine. … HZT-501 is under investigation by Horizon Therapeutics, Inc., a privately held biopharmaceutical company.
Ethotoin
go.drugbank.com/drugs/DB00754ApprovedEthotoin is a hydantoin derivative and anticonvulsant. Ethotoin exerts an antiepileptic effect without causing general central nervous system depression.
Custirsen
go.drugbank.com/drugs/DB05487InvestigationalCustirsen is also being investigated in the treatment of primary brain tumors. … Custirsen is a benzopyran with potential antineoplastic activity.
XTL-6865
go.drugbank.com/drugs/DB06058InvestigationalXTL-6865 is a combination of two fully human monoclonal antibodies (Ab68 and Ab65) against the hepatitis C virus E2 envelope protein. … It is being developed to prevent HCV re-infection following a liver transplant and for the treatment of chronic HCV disease.
Fluasterone
go.drugbank.com/drugs/DB06250ExperimentalHas antiproliferative effects on HIV-1 and reduces HIV-1 replication.